Report of Foreign Issuer (6-k)
June 17 2016 - 5:01PM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2016
Commission File Number: 001-34661
DEHAIER MEDICAL SYSTEMS LIMITED
Dehaier Medical Systems Limited
Room 501, 83 Fuxing Road
Haidian District, Beijing 100856
People’s Republic of China
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Explanatory Note:
On June 17, 2016, our Audit Committee and Board of Directors
approved the appointment of HHC and the dismissal of Friedman LLP (“Friedman”). The decision
was due to Friedman’s inability to commit to a timeline in which to complete the 2015 audit and to form an opinion based
on the information provided to Friedman. Friedman’s report on the financial statements for the year ended December 31, 2014
did not contain an adverse opinion or a disclaimer of opinion, and was not qualified or modified as to uncertainty, audit scope,
or accounting principles. During the registrant's most recent fiscal year ended December 31, 2015 and preceding such dismissal,
Friedman notified us that they had not received sufficient information to satisfy their audit procedures of the Company’s
consolidated financial statements and, therefore, could not form an opinion due to the lack of such information. Friedman has advised
us that we have not provided sufficient evidence to establish the timing and nature of write-offs and reserves related to certain
accounts receivable, inventory, prepayments and other receivables, which, if investigated further, could impact the previously-issued
audit report or the underlying financial statements for the year ended December 31, 2014. Other than as mentioned here, there were
no disagreements with Friedman on any matter of accounting principles or practices, financial statement disclosure, or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of Friedman, would have caused it to make reference
to the subject matter of the disagreements in connection with its report.
Exhibits
The following document is filed herewith:
Exhibit
Number
|
|
Document
|
|
|
|
99.1
|
|
Letter from Friedman LLP dated June 17, 2016
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DEHAIER MEDICAL SYSTEMS LIMITED
|
|
|
|
June 17, 2016
|
By:
|
/s/ Ping Chen
|
|
|
Ping Chen
|
|
|
Chief Executive Officer
|
|
|
(Principal Executive Officer) and
|
|
|
Duly Authorized Officer
|
Lianluo Smart (NASDAQ:LLIT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lianluo Smart (NASDAQ:LLIT)
Historical Stock Chart
From Jul 2023 to Jul 2024